1] Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, ON, Canada [2] Research Imaging Centre and Vivian M Rakoff PET Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada.
1] Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, ON, Canada [2] Research Imaging Centre and Vivian M Rakoff PET Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada [3] Human Brain Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada [4] Department of Pharmacology, University of Toronto, Toronto, ON, Canada [5] Campbell Family Mental Health Research Institute, Toronto, ON, Canada.
Neuropsychopharmacology. 2014 Jan;39(2):311-8. doi: 10.1038/npp.2013.192. Epub 2013 Aug 7.
The dopamine system is a primary treatment target for cocaine dependence (CD), but research on dopaminergic abnormalities (eg, D2 receptor system deficiencies) has so far failed to translate into effective treatment strategies. The D3 receptor system has recently attracted considerable clinical interest, and D3 antagonism is now under investigation as a novel avenue for addiction treatment. The objective here was to evaluate the status and behavioral relevance of the D3 receptor system in CD, using the positron emission tomography (PET) radiotracer [(11)C]-(+)-PHNO. Fifteen CD subjects (many actively using, but all abstinent 7-240 days on scan day) and fifteen matched healthy control (HC) subjects completed two PET scans: one with [(11)C]-(+)-PHNO to assess D3 receptor binding (BPND; calculated regionally using the simplified reference tissue model), and for comparison, a second scan with [(11)C]raclopride to assess D2/3 binding. CD subjects also completed a behavioral battery to characterize the addiction behavioral phenotype. CD subjects showed higher [(11)C]-(+)-PHNO BPND than HC in the substantia nigra, which correlated with behavioral impulsiveness and risky decision making. In contrast, [(11)C]raclopride BPND was lower across the striatum in CD, consistent with previous literature in 2 week abstinence. The data suggest that in contrast to a D2 deficiency, CD individuals may have heightened D3 receptor levels, which could contribute to addiction-relevant traits. D3 upregulation is emerging as a biomarker in preclinical models of addiction, and human PET studies of this receptor system can help guide novel pharmacological strategies for treatment.
多巴胺系统是可卡因依赖(CD)的主要治疗靶点,但迄今为止,针对多巴胺能异常(例如,D2 受体系统缺陷)的研究未能转化为有效的治疗策略。D3 受体系统最近引起了相当大的临床关注,D3 拮抗剂现在正在作为一种新的成瘾治疗途径进行研究。本研究旨在使用正电子发射断层扫描(PET)示踪剂 [(11)C]-(+)-PHNO 评估 CD 中 D3 受体系统的状态和行为相关性。15 名 CD 受试者(许多正在积极使用,但在扫描日之前均已戒断 7-240 天)和 15 名匹配的健康对照(HC)受试者完成了两次 PET 扫描:一次使用 [(11)C]-(+)-PHNO 评估 D3 受体结合(BPND;使用简化参考组织模型在区域上计算),并进行比较,第二次扫描使用 [(11)C]raclopride 评估 D2/3 结合。CD 受试者还完成了行为学测试,以表征成瘾行为表型。与 HC 相比,CD 受试者的黑质中 [(11)C]-(+)-PHNO BPND 更高,与行为冲动性和冒险决策相关。相比之下,CD 患者的纹状体中 [(11)C]raclopride BPND 较低,这与 2 周戒断期的先前文献一致。数据表明,与 D2 缺乏相反,CD 个体可能具有更高的 D3 受体水平,这可能导致与成瘾相关的特征。D3 上调正在成为成瘾的临床前模型中的生物标志物,并且对该受体系统的人类 PET 研究可以帮助指导治疗的新型药理学策略。